Safety and Effectiveness of Rasagiline in Chinese Patients with Parkinson’s Disease: A Prospective, Multicenter, Non-interventional Post-marketing Study

Wen Su, Zhanhua Liang, Wei Mao, Ming Shao, Xingyue Hu, Yuncheng Wu, Wenshi Wei, Zhenguo Liu, Kezhong Zhang, Beisha Tang, Shuai Cao, Zhuolun Song and Haibo Chen ()
Additional contact information
Wen Su: Beijing Hospital
Zhanhua Liang: The First Affiliated Hospital of Dalian Medical University
Wei Mao: Xuanwu Hospital, Capital Medical University
Ming Shao: The Affiliated Brain Hospital of Guangzhou Medical University
Xingyue Hu: Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Yuncheng Wu: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Wenshi Wei: Huadong Hospital Affiliated to Fudan University
Zhenguo Liu: Xinhua Hospital, Shanghai JiaoTong University School of Medicine
Kezhong Zhang: The First Affiliated Hospital of Nanjing Medical University
Beisha Tang: Xiangya Hospital, Central South University
Shuai Cao: Lundbeck (Beijing) Pharmaceutical Consulting Co, Ltd.
Zhuolun Song: Lundbeck (Beijing) Pharmaceutical Consulting Co, Ltd.
Haibo Chen: Beijing Hospital

Drug Safety, 2023, vol. 46, issue 7, No 3, 637-646

Abstract: Abstract Introduction Rasagiline is indicated for treating idiopathic Parkinson’s disease (PD) as monotherapy and adjunct therapy to levodopa in patients. Objectives To assess the post-marketing safety and tolerability of rasagiline in Chinese PD patients, as well as its effectiveness in improving motor symptoms. Methods This prospective, non-interventional, multicenter, cohort study included PD patients administered rasagiline monotherapy or adjunct therapy to levodopa. The primary outcome was the incidence of adverse drug reactions (ADRs) according to MedDRA® (version 22.0), and the secondary outcomes were the Parkinson’s Disease Unified Rating Scale (UPDRS) part III, Clinical Global Impression-Severity (CGI-S), and Clinical Global Impression-Global-Improvement (CGI-I), assessed at Weeks 4, 12, and 24. Results In total, 734 patients, 95 in the monotherapy subgroup and 639 in the adjunct therapy subgroup, were included in the safety population. The incidence rates of all ADRs were comparable between the monotherapy (15.8%) and adjunct therapy (13.6%) subgroups. The most common ADRs by system organ class were nervous system disorders (5.6%), gastrointestinal disorders (3.3%), psychiatric disorders (1.8%), vascular disorders (1.2%), and general disorders and administration site conditions (1.1%). Five (0.7%) participants experienced 5 serious ADRs. Improvements in UPDRS part III, CGI-S and CGI-I at Weeks 4, 12 and 24 from baseline were observed. Conclusions Safety data in this study indicated no extra safety concerns. Rasagiline is generally safe and well tolerated in Chinese PD patients. The safety profile and tolerability were in line with the established safety profile. Moreover, rasagiline reduced the severity of PD motor symptoms, confirming findings by previous clinical trials.

Date: 2023
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-023-01288-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:46:y:2023:i:7:d:10.1007_s40264-023-01288-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-023-01288-2

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().